Intensive Urate-Lowering May Protect Kidneys in Type 2 Diabetes
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
Diabetic Nephropathy
Albuminuria Down in Adults With Newly Diagnosed T2DM
Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria
Finerenone Gets Priority Review for Diabetic Kidney Disease
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Canagliflozin Beneficial Even for Advanced Kidney Disease
Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m2 with no increase in AKI
Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Nephropathy Progression in Type 1 Diabetes Linked to Depression
Whether successful treatment of depression reduces the risk for progression needs to be determined.
Finerenone NDA Submitted for Diabetic Kidney Disease
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
Highlights From the New KDIGO Guideline on Diabetes and CKD
The new KDIGO guideline highlights specific management differences by CKD severity.
Patients With Diabetes and CVD on Empagliflozin Have Fewer CV, Renal Events
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
Efficacy of Endothelin Receptor Antagonists for Renal Protection in Diabetic Kidney Disease
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
- Loading...
Loading...
Next post in Diabetic Nephropathy
Loading... 
Loading...